As the global demand for injectables grows, so does the demand for innovative delivery systems. For lyophilised forms, dual-chamber systems offer advantages. They have been on the market since the mid-1980s, mainly for emergency or chronic medication. The systems have been developed for the convenience of the patients/caregivers, but they also offer benefits for the pharma/biotech companies in regards to low residual volume and increased API yield.
Innovative delivery: dual-chamber systems
BackgroundAs the global demand for injectables grows, so does the demand for innovative delivery systems. For lyophilised forms, dual-chamber systems offer advantages. They have been on the market since the mid-1980s, mainly for emergency or chronic medication. The systems have been developed for the convenience of the patients/caregivers, but they also offer benefits for the pharma/biotech companies in regards to low residual volume and increased API yield.
Oxford Nanopore wins over Amgen
Latest NewsOxford Nanopore Technologies has impressed Amgen with its genetic sequencing technology. The US biopharma major has invested £50m in the Oxford-based company.
French Acticor Biotech raises €15.3m
Latest NewsIn a Series B financing round, INSERM spin-off Acticor Biotech has raised €15.3m from European and Asian investors. The new financing will go towards the launch off the first Phase II clinical trial of its lead candidate ACT017 in acute ischemic stroke.
HiFiBiO bags immuno-oncology specialist H-Immune
Latest NewsMultinational biotherapeutics company HiFiBiO Therapeutics announced that it has taken over early stage biotech H-Immune Therapeutics. With the acquisition of the French Atomic Energy Commission spin-out, HiFiBiO aims to strengthen its strategic focus on targetting differenct T cell subsets and combat cancer.
Phase III success for Roche breast cancer drug
Latest NewsRoche has announced that in a Phase III trial, its antibody-drug conjugate Kadcyla showed improved invasive disease-free survival in breast cancer patients.
Pioneers in the synbio revolution
BackgroundIs synthetic biology on the cusp of unlocking the next industrial revolution? A major roadblock is the ability to synthesise DNA for R&D in ways that are both cheap and efficient. Established players in the field believe the answer lies in miniaturising standard chemical processes and running them in parallel systems. But the new kids on the block are betting on a completely new process that involves enzymes.
Targovax reports promising disease-free survival (DFS) data
Latest NewsCutting time to market for high quality therapeutics
BackgroundThe demand for the fast and robust development of manufacturing cell lines is ever growing, with an increasing number of therapeutic proteins in development. To fulfill these needs, Celonic engineered the cell line kit CHOvolution, which equips users with everything required for the development of mammalian cell lines and provides an integrated support system for assistance.
EU set to speed up switch to bioeconomy by new action plan
Latest NewsSix years after the European Commission created the world’s first bioeconomy strategy and action plan, it presented a new action plan aimed at moving faster towards a climate-neutral, sustainable, biobased industry.
Bacterial antigen mimicry drives MS
Latest NewsT cells target a bacterial variant of a human enzyme promoting autoimmune diseases such as Multiple Sclerosis (MS).